Trials / Completed
CompletedNCT00251966
ASTERIX: Low Dose ASA and Nexium
A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 960 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole |
Timeline
- Start date
- 2004-05-01
- Completion
- 2005-09-01
- First posted
- 2005-11-11
- Last updated
- 2009-03-12
Locations
94 sites across 11 countries: Australia, Bulgaria, Canada, Germany, Greece, Hong Kong, Hungary, Italy, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00251966. Inclusion in this directory is not an endorsement.